I

Intensity Therapeutics Inc
NASDAQ:INTS

Watchlist Manager
Intensity Therapeutics Inc
NASDAQ:INTS
Watchlist
Price: 0.3876 USD -2%
Market Cap: $23.3m

Intensity Therapeutics Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Intensity Therapeutics Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
I
Intensity Therapeutics Inc
NASDAQ:INTS
Other Items
$6.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$5.9B
CAGR 3-Years
-108%
CAGR 5-Years
31%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$3B
CAGR 3-Years
-22%
CAGR 5-Years
8%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Other Items
-$1.3B
CAGR 3-Years
13%
CAGR 5-Years
33%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$1.1B
CAGR 3-Years
-40%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
$691.2m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Intensity Therapeutics Inc
Glance View

Market Cap
23.3m USD
Industry
Biotechnology

Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Westport, Connecticut and currently employs 3 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing an approach to treat solid tumor cancers. The company leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The firm's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. The company also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725).

INTS Intrinsic Value
0.0285 USD
Overvaluation 93%
Intrinsic Value
Price
I

See Also

What is Intensity Therapeutics Inc's Other Items?
Other Items
6.4m USD

Based on the financial report for Dec 31, 2024, Intensity Therapeutics Inc's Other Items amounts to 6.4m USD.

Back to Top